{"id":618152,"date":"2022-09-23T20:28:01","date_gmt":"2022-09-23T20:28:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=618152"},"modified":"2022-09-23T20:28:01","modified_gmt":"2022-09-23T20:28:01","slug":"epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-marinus-pharmaceuticals-takeda-ucb-biopharma-zynerba-pharma","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-marinus-pharmaceuticals-takeda-ucb-biopharma-zynerba-pharma_618152.html","title":{"rendered":"Epilepsy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies &#8211; Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma,"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663917742.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Epilepsy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma,\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663917742.jpeg\" alt=\"Epilepsy Market to Register Incremental Growth During the Forecast Period (2022-2032), Asserts DelveInsight | Key Companies - Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma,\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cEpilepsy Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\" target=\"_blank\"><strong>Epilepsy market<\/strong><\/a> is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">According to the National Institute of Neurological Disorders and Stroke (NINDS), epilepsies are a spectrum of brain disorders ranging from severe, life-threatening, and disabling, to ones that are much more benign. In epilepsy, the normal pattern of neuronal activity becomes disturbed, causing strange sensations, emotions, and behavior or sometimes convulsions, muscle spasms, and loss of consciousness.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Epilepsy signs and symptoms include: temporary confusion, staring spell, uncontrollable jerking movements of the arms and legs, loss of consciousness or awareness and psychic symptoms.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Epilepsy Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Epilepsy market size is anticipated to grow with a significant CAGR during the study period (2019-2032)&nbsp;<\/li>\n<li>Certain factors like age, family history, head injury, stroke, dementia and others may increase the risk of epilepsy&nbsp;<\/li>\n<li><strong>Key Epilepsy Companies:<\/strong> Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma, Neurocrine Bioscience, Cerevel Therapeutics, PTC Therapeutics, and others<\/li>\n<li><strong>Key Epilepsy Therapies:<\/strong> Ganaxolone, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478, NBI-827104, CVL-865, and others<\/li>\n<li>The Epilepsy epidemiology based on gender analyzed that epilepsy is more prevalent among males than in females&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Market Report<\/a><\/strong>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Epilepsy Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Epilepsy market report covers a descriptive overview and comprehensive insight of the Epilepsy Epidemiology and Epilepsy market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Epilepsy market report provides insights on the current and emerging therapies.<\/li>\n<li>Epilepsy market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Epilepsy market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Epilepsy market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Epilepsy market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Epilepsy market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Epilepsy<\/li>\n<li>Prevalent Cases of Epilepsy by severity<\/li>\n<li>Gender-specific Prevalence of Epilepsy<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Epilepsy&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market<\/strong> &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Epilepsy market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as <strong>Zygel, ACT-709478,<\/strong>&nbsp;and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Epilepsy epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Epidemiological Insights<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Specialized multidisciplinary care<\/li>\n<li>Constructive Efforts<\/li>\n<li>Promising Emerging Epilepsy Therapies<\/li>\n<li>Increase in Research and Development<\/li>\n<li>Government Initiatives and Funding<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Ganaxolone:<\/strong> Marinus Pharmaceuticals<\/li>\n<li><strong>Soticlestat:<\/strong> Takeda<\/li>\n<li><strong>Staccato Alprazolam:<\/strong> UCB Biopharma<\/li>\n<li><strong>Zygel:<\/strong> Zynerba Pharma<\/li>\n<li><strong>ACT-709478\/ NBI-827104:<\/strong> Neurocrine Bioscience<\/li>\n<li><strong>CVL-865:<\/strong> Cerevel Therapeutics<\/li>\n<li><strong>Vatiquinone:<\/strong> PTC Therapeutics<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Epilepsy Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Epilepsy Companies:<\/strong> Marinus Pharmaceuticals, Takeda, UCB Biopharma, Zynerba Pharma, Neurocrine Bioscience, Cerevel Therapeutics, PTC Therapeutics, and others<\/li>\n<li><strong>Key Epilepsy Therapies:<\/strong> Ganaxolone, Soticlestat, Staccato Alprazolam, Zygel, ACT-709478, NBI-827104, CVL-865, and others<\/li>\n<li><strong>Epilepsy Therapeutic Assessment:<\/strong> Epilepsy current marketed and Epilepsy emerging therapies<\/li>\n<li><strong>Epilepsy Market Dynamics:<\/strong>&nbsp; Epilepsy market drivers and Epilepsy market barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Epilepsy Market Access and Reimbursement&nbsp;<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Epilepsy Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Heterogeneity Barrier<\/li>\n<li>Differential Epilepsy Diagnosis<\/li>\n<li>Specialized multidisciplinary care<\/li>\n<li>Increase in Research and Development<\/li>\n<li>Government Initiatives and Funding<\/li>\n<li>Epilepsy Therapeutic Barriers<\/li>\n<li>Public Health Barriers<\/li>\n<li>Challenges during Clinical Studies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Epilepsy Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Epilepsy<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Epilepsy<\/p>\n<p style=\"text-align: justify;\">4. Epilepsy Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Epilepsy Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Epilepsy Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Epilepsy Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Epilepsy&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Epilepsy Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Epilepsy Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Epilepsy Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Epilepsy Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Epilepsy Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Epilepsy Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Epilepsy Market Drivers<\/p>\n<p style=\"text-align: justify;\">16. Epilepsy Market Barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Epilepsy Appendix<\/p>\n<p style=\"text-align: justify;\">18. Epilepsy Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Epilepsy treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/epilepsy-market-insight?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Epilepsy Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-marinus-pharmaceuticals-takeda-ucb-biopharma-zynerba-pharma\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-marinus-pharmaceuticals-takeda-ucb-biopharma-zynerba-pharma\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cEpilepsy Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/epilepsy-market-to-register-incremental-growth-during-the-forecast-period-20222032-asserts-delveinsight-key-companies-marinus-pharmaceuticals-takeda-ucb-biopharma-zynerba-pharma_618152.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-618152","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/618152","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=618152"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/618152\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=618152"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=618152"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=618152"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}